CN108567820B - 一种用于肿瘤治疗的中药组合物及其制备方法 - Google Patents
一种用于肿瘤治疗的中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN108567820B CN108567820B CN201710147162.1A CN201710147162A CN108567820B CN 108567820 B CN108567820 B CN 108567820B CN 201710147162 A CN201710147162 A CN 201710147162A CN 108567820 B CN108567820 B CN 108567820B
- Authority
- CN
- China
- Prior art keywords
- percent
- traditional chinese
- chinese medicine
- medicine composition
- lung tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 126
- 239000000203 mixture Substances 0.000 title claims abstract description 86
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 148
- 239000000463 material Substances 0.000 claims abstract description 21
- 241000222336 Ganoderma Species 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 115
- 239000000243 solution Substances 0.000 claims description 41
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 32
- 239000007788 liquid Substances 0.000 claims description 30
- 239000000341 volatile oil Substances 0.000 claims description 29
- 244000197580 Poria cocos Species 0.000 claims description 25
- 235000008599 Poria cocos Nutrition 0.000 claims description 25
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 23
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 23
- 230000002829 reductive effect Effects 0.000 claims description 22
- 235000006679 Mentha X verticillata Nutrition 0.000 claims description 21
- 235000002899 Mentha suaveolens Nutrition 0.000 claims description 21
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims description 21
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 21
- 235000011477 liquorice Nutrition 0.000 claims description 21
- 241000205585 Aquilegia canadensis Species 0.000 claims description 20
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 claims description 19
- 244000035851 Chrysanthemum leucanthemum Species 0.000 claims description 19
- 238000000605 extraction Methods 0.000 claims description 19
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims description 18
- 241000112528 Ligusticum striatum Species 0.000 claims description 18
- 235000016639 Syzygium aromaticum Nutrition 0.000 claims description 18
- 244000223014 Syzygium aromaticum Species 0.000 claims description 18
- 235000017803 cinnamon Nutrition 0.000 claims description 18
- 238000001035 drying Methods 0.000 claims description 18
- 208000020816 lung neoplasm Diseases 0.000 claims description 16
- 235000006533 astragalus Nutrition 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 15
- 238000001914 filtration Methods 0.000 claims description 14
- 235000001188 Peltandra virginica Nutrition 0.000 claims description 13
- 239000002131 composite material Substances 0.000 claims description 13
- 239000003826 tablet Substances 0.000 claims description 13
- 238000005303 weighing Methods 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 12
- 229920000858 Cyclodextrin Polymers 0.000 claims description 11
- 239000000284 extract Substances 0.000 claims description 11
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 11
- 244000116484 Inula helenium Species 0.000 claims description 10
- 235000002598 Inula helenium Nutrition 0.000 claims description 10
- 229940107666 astragalus root Drugs 0.000 claims description 10
- 238000002791 soaking Methods 0.000 claims description 10
- 229940126680 traditional chinese medicines Drugs 0.000 claims description 10
- 241000045403 Astragalus propinquus Species 0.000 claims description 9
- 240000008397 Ganoderma lucidum Species 0.000 claims description 9
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 238000005325 percolation Methods 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 7
- 241001061264 Astragalus Species 0.000 claims description 6
- 241000212322 Levisticum officinale Species 0.000 claims description 6
- 241000219784 Sophora Species 0.000 claims description 6
- 239000001645 levisticum officinale Substances 0.000 claims description 6
- 239000006187 pill Substances 0.000 claims description 6
- 210000004233 talus Anatomy 0.000 claims description 6
- MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 claims description 5
- 239000012530 fluid Substances 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 238000007873 sieving Methods 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 230000001376 precipitating effect Effects 0.000 claims description 2
- 208000037841 lung tumor Diseases 0.000 claims 14
- 230000002685 pulmonary effect Effects 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 51
- 238000012360 testing method Methods 0.000 abstract description 13
- 230000000259 anti-tumor effect Effects 0.000 abstract description 10
- 241000628997 Flos Species 0.000 abstract description 7
- 239000009636 Huang Qi Substances 0.000 abstract description 6
- 241001619461 Poria <basidiomycete fungus> Species 0.000 abstract description 4
- 230000002708 enhancing effect Effects 0.000 abstract description 4
- 230000036737 immune function Effects 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 48
- 201000011510 cancer Diseases 0.000 description 31
- 210000004369 blood Anatomy 0.000 description 29
- 239000008280 blood Substances 0.000 description 29
- 210000000952 spleen Anatomy 0.000 description 29
- 230000036407 pain Effects 0.000 description 23
- 208000002193 Pain Diseases 0.000 description 22
- 229940079593 drug Drugs 0.000 description 19
- 238000011580 nude mouse model Methods 0.000 description 18
- 230000001737 promoting effect Effects 0.000 description 18
- 210000004185 liver Anatomy 0.000 description 16
- 210000002784 stomach Anatomy 0.000 description 16
- 230000006870 function Effects 0.000 description 15
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 13
- 201000005249 lung adenocarcinoma Diseases 0.000 description 13
- 210000004881 tumor cell Anatomy 0.000 description 13
- 230000017531 blood circulation Effects 0.000 description 11
- 210000002216 heart Anatomy 0.000 description 11
- 210000003734 kidney Anatomy 0.000 description 11
- 210000004072 lung Anatomy 0.000 description 11
- 230000035755 proliferation Effects 0.000 description 11
- 238000011160 research Methods 0.000 description 11
- 239000003053 toxin Substances 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 10
- 230000001717 pathogenic effect Effects 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 9
- 241000699660 Mus musculus Species 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 231100000765 toxin Toxicity 0.000 description 9
- 108700012359 toxins Proteins 0.000 description 9
- 206010011224 Cough Diseases 0.000 description 8
- 230000009471 action Effects 0.000 description 8
- 231100000331 toxic Toxicity 0.000 description 8
- 230000002588 toxic effect Effects 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 208000025865 Ulcer Diseases 0.000 description 7
- 235000009508 confectionery Nutrition 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 238000005728 strengthening Methods 0.000 description 7
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 6
- 208000005392 Spasm Diseases 0.000 description 6
- 230000036772 blood pressure Effects 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- 229960004397 cyclophosphamide Drugs 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 239000002398 materia medica Substances 0.000 description 6
- 206010007247 Carbuncle Diseases 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 5
- 201000007100 Pharyngitis Diseases 0.000 description 5
- 206010042674 Swelling Diseases 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- 230000001093 anti-cancer Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 210000000038 chest Anatomy 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 208000001848 dysentery Diseases 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000009401 metastasis Effects 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 235000019640 taste Nutrition 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- 231100000397 ulcer Toxicity 0.000 description 5
- 238000010792 warming Methods 0.000 description 5
- 206010002660 Anoxia Diseases 0.000 description 4
- 241000976983 Anoxia Species 0.000 description 4
- 241000721047 Danaus plexippus Species 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 206010017553 Furuncle Diseases 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 description 4
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 description 4
- 206010068319 Oropharyngeal pain Diseases 0.000 description 4
- 206010033557 Palpitations Diseases 0.000 description 4
- 230000007953 anoxia Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000007865 diluting Methods 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 229930014456 matrine Natural products 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 239000008055 phosphate buffer solution Substances 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 238000011729 BALB/c nude mouse Methods 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 208000006083 Hypokinesia Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000001914 calming effect Effects 0.000 description 3
- 210000000748 cardiovascular system Anatomy 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 229960005233 cineole Drugs 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 238000001784 detoxification Methods 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 238000010926 purge Methods 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 235000017709 saponins Nutrition 0.000 description 3
- 230000035900 sweating Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 2
- KQQXUARABJGCMS-UHFFFAOYSA-N 3-methylbutyl 2-hydroxy-2-phenylacetate Chemical group CC(C)CCOC(=O)C(O)C1=CC=CC=C1 KQQXUARABJGCMS-UHFFFAOYSA-N 0.000 description 2
- XVPBINOPNYFXID-JARXUMMXSA-N 85u4c366qs Chemical compound C([C@@H]1CCC[N@+]2(CCC[C@H]3[C@@H]21)[O-])N1[C@@H]3CCCC1=O XVPBINOPNYFXID-JARXUMMXSA-N 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
- 241000132012 Atractylodes Species 0.000 description 2
- TYPSVDGIQAOBAD-DZGCQCFKSA-N Atractylone Chemical compound C([C@]1(C)C2)CCC(=C)[C@@H]1CC1=C2OC=C1C TYPSVDGIQAOBAD-DZGCQCFKSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 235000017443 Hedysarum boreale Nutrition 0.000 description 2
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 240000004371 Panax ginseng Species 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 230000018199 S phase Effects 0.000 description 2
- 244000272264 Saussurea lappa Species 0.000 description 2
- 235000006784 Saussurea lappa Nutrition 0.000 description 2
- 201000010001 Silicosis Diseases 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 208000033809 Suppuration Diseases 0.000 description 2
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 241000711955 Turkey rhinotracheitis virus Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000018678 bone mineralization Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000007541 cellular toxicity Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 208000023819 chronic asthma Diseases 0.000 description 2
- 208000013116 chronic cough Diseases 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- 230000000916 dilatatory effect Effects 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229930015582 oxymatrine Natural products 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 201000005665 thrombophilia Diseases 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010049589 Afterbirth pain Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 240000005250 Chrysanthemum indicum Species 0.000 description 1
- 235000018959 Chrysanthemum indicum Nutrition 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 244000075634 Cyperus rotundus Species 0.000 description 1
- 235000016854 Cyperus rotundus Nutrition 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 201000008197 Laryngitis Diseases 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 240000000233 Melia azedarach Species 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000001140 Night Blindness Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 208000008350 Pruritus Vulvae Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010057071 Rectal tenesmus Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 241000246044 Sophora flavescens Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 206010056530 Vulvovaginal pruritus Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229940124277 aminobutyric acid Drugs 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- TYPSVDGIQAOBAD-UHFFFAOYSA-N atractylone Natural products C1C2(C)CCCC(=C)C2CC2=C1OC=C2C TYPSVDGIQAOBAD-UHFFFAOYSA-N 0.000 description 1
- 208000027697 autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency Diseases 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 208000010515 dystocia Diseases 0.000 description 1
- 230000004821 effect on bone Effects 0.000 description 1
- 230000000040 effect on leukemia Effects 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 208000003512 furunculosis Diseases 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 208000012271 tenesmus Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/234—Cnidium (snowparsley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明提供一种用于肿瘤治疗的中药组合物及其制备方法,包括以下原料制备而成:苦参、野菊花、金银花、薄荷、茯苓、苍术、肉桂、丁香、黄芪、灵芝、川芎、木香和甘草。本发明所述中药组合物的组方经大小白鼠药效试验证明抗肿瘤效果显著;且药材获取简单,成本相对低廉,具有增强机体免疫功能,抗肿瘤的作用。
Description
技术领域
本发明属于中药及中药制备领域,涉及一种用于肿瘤治疗的中药组合物及其制备方法。
背景技术
肿瘤(tumour)是指机体在各种致瘤因子作用下,局部组织细胞增生所形成的新生物(neogrowth),因为这种新生物多呈占位性块状突起,也称赘生物(neoplasm)。根据新生物的细胞特性及对机体的危害性程度,又将肿瘤分为良性肿瘤和恶性肿瘤两大类,而癌症即为恶性肿瘤的总称。癌症(cancer),亦称恶性肿瘤(malignant neoplasm),为由控制细胞生长增殖机制失常而引起的疾病。癌细胞除了生长失控外,还会局部侵入周遭正常组织甚至经由体内循环系统或淋巴系统转移到身体其他部分。癌症是一大类恶性肿瘤的统称。癌细胞的特点是无限制、无止境地增生,使患者体内的营养物质被大量消耗;癌细胞释放出多种毒素,使人体产生一系列症状;癌细胞还可转移到全身各处生长繁殖,导致人体消瘦、无力、贫血、食欲不振、发热以及严重的脏器功能受损等等。与之相对的有良性肿瘤,良性肿瘤则容易清除干净,一般不转移、不复发,对器官、组织只有挤压和阻塞作用,但癌症(恶性肿瘤)还可破坏组织、器官的结构和功能,引起坏死出血合并感染,患者最终由于器官功能衰竭而死亡。
目前,恶性肿瘤的治疗主要采用手术治疗,化学治疗或放射线治疗等,其中手术治疗术后恢复困难,化学治疗和放射线治疗等对人体伤害较大。
现在的恶性肿瘤治疗中,抗肿瘤药物市场近年来呈逐年增长的势头,但由于肿瘤病人逐年增加,且多数抗肿瘤药物毒副作用较大,因此发明一种效果明显,且副作用小的抗癌药物具有重要的意义。
发明内容
本发明所要解决的技术问题在于提供一种用于肿瘤治疗的中药组合物,本发明所要解决的另一技术问题在于提供一种用于肿瘤治疗的中药组合物的制备方法。
为解决上述技术问题,本发明采用了以下技术方案实现:本发明所要解决的问题是提供一种用于肿瘤治疗的中药组合物。
本发明的一种用于肿瘤治疗的中药组合物,包括以下重量配比的原料制成:
苦参3%-12%,野菊花5%-15%,金银花2%-12%,薄荷5%-15%,茯苓5%-15%,苍术10%-20%,肉桂0.5%-3%,丁香0.5%-3%,黄芪3%-12%,灵芝5%-15%,川芎10%-20%,木香5%-12%,甘草2%-10%。
进一步的,所述用于肿瘤治疗的中药组合物包括以下重量配比的原料制成:
苦参5%-10%,野菊花5%-10%,金银花3%-8%,薄荷5%-10%,茯苓5%-10%,苍术12%-20%,肉桂0.5%-3%,丁香0.5%-3%,黄芪5%-10%,灵芝5%-10%,川芎11%-15%,木香8%-12%,甘草3%-8%。
进一步的,所述用于肿瘤治疗的中药组合物包括以下重量配比的原料制成:
苦参6%-10%,野菊花6%-9%,金银花3%-6%,薄荷6%-9%,茯苓6%-9%,苍术15%-18%,肉桂1%-3%,丁香0.5%-1.5%,黄芪6%-10%,灵芝6%-10%,川芎12%-15%,木香8%-11%,甘草3%-6%。
进一步的,所述用于肿瘤治疗的中药组合物的剂型为:注射剂、蜜炼丸剂、水合丸剂、胶囊、片剂、滴丸剂、散剂、口服液体药物、凝胶剂、煎膏剂、浸膏剂或膜剂。
本申请还提供一种所述的用于肿瘤治疗的中药组合物的制备方法,包括以下步骤:
(1)按照上述之一重量配比称取各中药成分,分别粉碎至粒度至10目-100目过筛后混合均匀;
(2)配制浓度为40%-95%的乙醇溶液备用;采用制备的所述浓度为40%-95%的乙醇溶液将混合均匀后的中药浸润10-48小时,将浸润后的中药混合物分次加入渗漉桶,轻压铺平;
(3)将所述配制的浓度为40%-95%的乙醇溶液加入到步骤(2)中的渗漉桶中,加至超过药材表面1-2cm,浸泡预设时间后,将剩余乙醇进行渗漉,保留药渣备用;所得醇液减压浓缩,干燥得到中药复合粉末A;
(4)将所述药渣加2-10倍药渣量的水,水煎提取0.5-2h,离心过滤,药液减压浓缩干燥得到中药复合粉末B,将所述中药复合粉末A和中药复合粉末B混合均匀得到中药组合物。
进一步的,所述步骤(1)中各种药材粉碎粒度至20-40目;最优选24目;所述步骤(2)和(3)中所配制的乙醇浓度为60%-80%,最优选70%。
优选的,所述步骤(2)中将混合均匀后的中药浸润18-30小时;最优选24小时;所述步骤(3)中浸泡时间为2-48小时,优选18-36小时。
本申请还提供一种用于肿瘤治疗的中药组合物的制备方法,包括以下步骤:
(1)按照所述重量配比称取川芎、苍术、木香、丁香、肉桂、薄荷加适量水提取挥发油后,加环糊精包合,水煎液过滤另器收集作为剩余药液备用;
(2)将挥发油提取后得到的药渣与按所述重量配比称取的茯苓,黄芪,野菊花,灵芝,金银花,苦参,甘草加水煎煮,过滤药液,将过滤后的药液与提取挥发油后得到的剩余药液合并得到中药混合药液;
(3)将得到的中药混合药液通过水浴浓缩至清膏,醇沉,加乙醇使含醇量达到50%-80%得到中药混合醇液;
(4)将所述中药混合醇液进行减压浓缩,干燥后,加入挥发油环糊精包合物制得中药组合物。
进一步的,所述步骤(1)中挥发油提取溶剂用量为4-15倍所述药材量的水,提取时间2-12小时;得到的挥发油在40摄氏度以下进行环糊精包合,包合时间1~10小时。
优选的,所述步骤(1)中挥发油提取溶剂用量为4-8倍所述药材量的水,最优选的可以为6倍;所述步骤(1)中进行环糊精包合时间为2-8小时,最优选6小时。
进一步的,所述步骤(2)包括:将挥发油提取后得到的药渣与按所述重量配比称取的茯苓,黄芪,野菊花,灵芝,金银花,苦参,甘草加10~15倍药材量的水煎煮2~5次,每次1-2小时;将煎煮得到的药液进行过滤,将过滤后的药液与提取挥发油后得到的剩余药液合并得到中药混合药液。
进一步的,所述步骤(3)包括:将得到的中药混合药液通过水浴进行浓缩,浓缩至相对密度为1.06-1.08的清膏,加入乙醇使含醇量达60%,静置12小时以上得到中药混合醇液。
本申请还提供一种所述的用于肿瘤治疗的中药组合物的制备方法,包括以下步骤:
(1)按照所述重量配比称取各中药成分;
(2)配制浓度为40%-80%的乙醇溶液备用;将混合均匀的中药中加入所述配制的乙醇溶液,加热回流提取1-4次,每次1-2小时,将提取液合并,减压回收乙醇后进行浓缩干燥,得到中药组合物。
进一步的,所述步骤(2)中配制浓度为50%-70%的乙醇溶液备用,优选的配置浓度为60%的乙醇溶液。
本发明所选药剂原料:
1、苦参:苦,寒。归心、肺、肾、大肠经。清热燥湿,祛风杀虫。主治湿热泻痢,肠风便血,黄疸,小便不利,水肿,带下,阴痒,皮肤瘙痒等。苦参含有苦参碱、氧化苦参碱、脱氧苦参碱等多种活性抗癌成分,同时还有扩张血管、抗炎、升高白细胞、中枢系统抑制等多种不同作用。苦参碱可抑制人肝癌SMMC-7721,人胃腺癌SGC-7901细胞的增殖,可使细胞聚集于S期,起到诱导分化的作用,可明显抑制肿瘤细胞与内皮细胞的黏附,减轻内皮细胞的通透性,减少肿瘤的转移;具有很好的抗肿瘤作用。在抑制肿瘤生长的同时,能够扩张血管,改善肿瘤脏器的缺血、瘀血情况,还能够改变中枢对疼痛的反应,从而消除引起疼痛的原因,达到止痛的目的。其主要作用机理是:(1)直接杀伤肿瘤细胞;(2)直接作用于靶DNA而抗肿瘤;(3)通过影响细胞周期而抗肿瘤;(4)通过诱导肿瘤细胞凋亡的发生而抗肿瘤。大量的实验研究表明,苦参具有明显的止痛、抗癌、提高免疫力、止血等作用。能明显减轻化疗毒副作用,提高患者生活质量,在化疗当中对骨髓、肝、肾等脏器有良好的保护作用。
2、野菊花:味苦;辛;性平。入肺;肝经。清热解毒;疏风平肝。主治疔疮;痈疽;丹毒;湿疹;皮炎;风热感冒;咽喉肿痛;高血压病。《本草汇言》载:“破血疏肝;解疔散毒。主妇人腹内宿血,解天行火毒丹疔。洗疮疥,又能去风杀虫。”现代医学研究证实,野菊花具有广谱抗菌作用,对多数皮肤真菌、金黄色葡萄球菌、痢疾杆菌、绿脓杆菌和流感病毒均有较强的抑制作用,还具有降压、降脂、预防感冒的作用。
3、金银花:性甘、寒。归肺、胃经。清热解毒,消炎退肿。主治外感风热或温病发热,中暑,热毒血痢,痈肿疔疮,喉痹,多种感染性疾病。具有抗病原微生物作用,抗毒作用,抗炎作用,可明显促进炎性细胞吞噬功能作用,降血脂作用,对肉瘤S180和艾式腹水癌有明显的细胞毒作用。
4、薄荷:味辛,性凉,归肺、肝经。宣散风热,清利头目,利咽透疹,疏肝解郁。主治风热表证,头痛目赤,咽喉肿痛,麻疹不透,风疹瘙痒,肝郁胁痛。《本草新编》:“薄荷,不特善解风邪,尤善解忧郁,用香附以解郁,不若用薄荷解郁之更神。薄荷入肝胆之经,善解半表半里之邪,较柴胡更为轻清。”。薄荷还具有保肝利胆的作用,抗炎抗微生物的作用。
5、茯苓:味甘;淡;性平。入心;脾;肺;肾经。渗湿利水;健脾和胃;宁心安神。主治小便不利;水肿胀满;痰饮咳逆;呕吐;脾虚食少;泄渲;心悸不安;失眠健忘;遗精白浊。《别录》载:“止消渴,好睡,大腹,淋沥,膈中痰水,水肿淋结。开胸腑,调脏气,伐肾邪,长阴,益气力,保神守中。”现代医学研究证实,茯苓对金黄色葡萄球菌、大肠杆菌、变形杆菌等均有抑制作用,能杀死钩端螺旋体等细菌,对消化系统、血液系统及中枢神经系统具有一定的保护作用,此外茯苓聚糖含量很高,可抗肿瘤活性。
6、苍术:性辛、味苦,温。归脾、胃、肝经。功能主治燥湿健脾,祛风散寒,明目。用于脘腹胀满,泄泻水肿,脚气痿躄,风湿痹痛,风寒感冒,夜盲。对心血管系统的影响显示,苍术对蟾蜍心脏有轻度抑制作用,对蟾蜍后肢血管有轻度扩张作用。苍术浸膏小剂量静脉注射,可使家兔血压轻度上升,大剂量则使血压下降。苍术燥湿健脾功效相关的药理作用为调整胃肠运动功能、抗溃疡、保肝、抑菌等。苍术主要有效成分是以β-桉叶醇及茅术醇为代表的挥发油。苍术对血糖的影响,抗缺氧、中枢抑制、抗肿瘤、促进骨骼钙化及对心血管系统的影响等作用,则是其药理作用的现代研究进展。临床研究报道,苍术水煎剂能明显促进肝蛋白的合成,生药及其所含苍术醇、苍术酮、B-桉叶醇对四氯化碳诱发的一级培养鼠肝细胞损害均有显著的预防作用。
7、肉桂:辛、甘,大热,归肾、脾、心、肝经,功效补火助阳,引火归源,散寒止痛,活血通经。补元阳,暖脾胃,除积冷,通血脉。《本草正》:桂,善平肝木之阴邪,而不知善助肝胆之阳气,惟其味甘,故最补脾土,凡肝邪克土而无火者,用此极妙。
8、丁香:辛温芳香,归脾、胃、肺、肾经,具有温中降逆、行气止痛之功,为治呕逆之要药。《本草正》:温中快气。治上焦呃逆,除胃寒泻痢,七情五郁。《本草经疏》谓之:“辛温暖脾胃而行滞气……而香气又能走窍除秽浊也。”
9、黄芪:以补虚为主,能补气固表,利尿托毒,排脓,敛疮生肌。用于气血不足、疮疡内陷、脓成不溃或久溃不敛者。黄芪具有很好的托毒生肌的功能,即久不愈合的脓肿化脓生肌。黄芪主要成分为黄芪皂苷、黄芪多糖、氨基丁酸、微量元素(硒、锰、铁、锌、铜)和钙等;现代医学研究表明,黄芪内含而多种抗菌有效成分,而且能增强机体的免疫功能,因此还能用于预防某些传染病的发生。《本草逢原》载:“黄芪能补五脏诸虚,治脉弦自汗,泻阴火,去肺热,无汗则发,有汗则止。”是增进抵抗力和防御疾病的良药。大量的临床研究证实,黄芪具有保护心脏及肾脏、双向调节血糖及血压、抗缺氧、抗自由基氧化、抗衰老、抗肿瘤及增强机体免疫力等功效。
10、灵芝:味甘苦、性平,归肺;心;脾;肾经。益气血;安心神;健脾胃。主治:虚劳;心悸;失眠;头晕;神疲乏力;久咳气喘;冠心病;矽肺;肿瘤。《神农本草经》:“赤芝,味苦平。主胸中结,益心气,补中,增慧智,不忘。现代医学研究发现,灵芝可有效地扩张冠状动脉,增加冠脉血流量,改善心肌微循环,增强心肌氧和能量的供给,因此,对心肌缺血具有保护作用,可广泛用于冠心病、心绞痛等的治疗和预防。对高血脂病患者,灵芝可明显降低血胆固醇、脂蛋白和甘油三脂,并能预防动脉粥样硬化斑块的形成。对于粥样硬化斑块已经形成者,则有降低动脉壁胆固醇含量、软化血管、防止进一步损伤的作用。
11、川芎:入肝、脾、三焦三经。功用主治行气开郁,法风燥湿,活血止痛。治风冷头痛旋晕,胁痛腹疼,寒痹筋挛,经闭,难产,产后瘀阻块痛,痈疽疮疡。用于月经不调,经闭痛经,瘕腹痛,胸胁刺痛,跌扑肿痛,头痛,风湿痹痛。《纲目》载:″燥湿,止泻痢,行气开郁。″川芎嗪解除血管平滑肌(主动脉条)痉挛(肾上腺素、氯化钾引起)。是活血化瘀的良药。川芎具有活血行气、祛风止痛之功效实验证实用川芎可减缓大、小鼠及犬的放射性照射与氮芥損伤,因而对肿瘤病人有明显的保护作用,且具有一定的抗癌功效,对白血病癌细胞有抑制作用。川芎的抗癌作用主要体现在降低肿瘤细胞的表面活性,使其不易粘附成团而易于在血流中被单个杀死;改变癌症患者的血液高凝状态,抑制癌细胞转移。
12、木香:辛、苦、温,归脾胃经,具有行气止痛,健脾消食的作用。《本草纲目》:“木香,乃三焦气分之药,能升降诸气;中气不运,皆属于脾,故中焦气滞宜之者,脾胃喜芳香也”;现代药理发现木香对胃肠道有兴奋和抑制的双向调节作用,能加快胃肠蠕动、促进胃排空。木香具有行气止痛、健脾消食之功效,用于治疗胸脘胀痛、泻痢后重、食积不消等;现代医学研究证明,木香具有治疗癌症的作用。
13、甘草:补气固表,温中,调和药物偏性,不伤正气。味甘;性平。归心;肺;脾;胃经。补脾益气;清热解毒;祛痰止咳;缓急止痛;调和诸药。主治脾胃虚弱;倦怠乏力;心悸气短;咳嗽痰多;脘腹四脚挛急疼痛;痈肿疮毒;缓解药物毒性。《本草纲目》载:“诸药中甘草为君。治七十二种乳石毒,解一千二百般草本毒,调和从药有功。”现代医学研究证实,甘草有较强的解毒作用,还有抗溃疡、抗炎症、镇痉镇咳、降血压、降血脂、抗癌作用,广泛用于治疗咽喉炎、喉炎、气管炎、支气管炎、哮喘、咳嗽、咳血等疾病,此外还具有抗胃溃疡、抗胃炎作用。
本发明的有益效果还在于:
本发明中以苦参大苦大寒,清热燥湿重用为君。苦参大苦大寒,其退热泄降,荡涤湿火之效,能杀湿热所生之毒。且苦参含有苦参碱、氧化苦参碱、脱氧苦参碱等多种活性抗癌成分,同时还有扩张血管、抗炎、升高白细胞、中枢系统抑制等多种不同作用。苦参碱可抑制人肝癌SMMC-7721,人胃腺癌SGC-7901细胞的增殖,可使细胞聚集于S期,起到诱导分化的作用,可明显抑制肿瘤细胞与内皮细胞的黏附,减轻内皮细胞的通透性,减少肿瘤的转移;具有很好的抗肿瘤作用。在抑制肿瘤生长的同时,能够扩张血管,改善肿瘤脏器的缺血、瘀血情况,还能够改变中枢对疼痛的反应,从而消除引起疼痛的原因,达到止痛的目的。以野菊花、金银花、薄荷疏风清热,以清肺卫之热毒;茯苓、苍术健脾祛湿,以祛脾胃之湿滞。共奏清热燥湿解毒之效以为臣。其中薄荷宣散风热,清利头目,利咽透疹,疏肝解郁,兼具保肝利胆的作用,抗炎抗微生物的作用。金银花清热解毒,消炎退肿;具有抗病原微生物作用,抗毒作用,抗炎作用,可明显促进炎性细胞吞噬功能作用,降血脂作用,对肉瘤S180和艾式腹水癌有明显的细胞毒作用。茯苓味甘;淡;性平。入心;脾;肺;肾经。“止消渴,好睡,大腹,淋沥,膈中痰水,水肿淋结。开胸腑,调脏气,伐肾邪,长阴,益气力,保神守中。”且现代医学证明茯苓的茯苓聚糖含量很高,可抗肿瘤活性;茯苓对消化系统、血液系统及中枢神经系统具有一定的保护作用。苍术主要有效成分是以β-桉叶醇及茅术醇为代表的挥发油。苍术对血糖的影响,抗缺氧、中枢抑制、抗肿瘤、促进骨骼钙化及对心血管系统的影响等作用。则苦参为君,与野菊花、金银花、薄荷;茯苓、苍术配伍功效更佳。湿热一去,则阳亦衰微矣。故大队苦寒之中,少佐丁香、肉桂补火助阳以为反佐,防湿去阳微而功亏一篑,且少火亦可生气,可保人之元阳不熄。黄芪、灵芝益气扶正,固本培元。温阳与益气共用,可防止诸药苦寒太过,伤人脾胃。且传统医学认为灵芝主治:虚劳;心悸;失眠;头晕;神疲乏力;久咳气喘;冠心病;矽肺;肿瘤;并能够对心肌缺血具有保护作用。现代医学研究表明,黄芪内含而多种抗菌有效成分,而且能增强机体的免疫功能,黄芪具有保护心脏及肾脏、双向调节血糖及血压、抗缺氧、抗自由基氧化、抗衰老、抗肿瘤及增强机体免疫力等功效。川芎具有行气开郁,法风燥湿,活血止痛之功效并能够降低癌细胞表面活性。临床研究报道,川芎的抗癌作用主要体现在降低肿瘤细胞的表面活性,使其不易粘附成团而易于在血流中被单个杀死;改变癌症患者的血液高凝状态,抑制癌细胞转移。而木香具有行气止痛之用,且在《神农本草经》中记载:主邪气,辟毒疫,强志,主淋露。《本草经集注》中亦有记载:疗毒肿,消恶气。木香配合川芎具有显著的抗肿瘤的功效,可抗肿瘤活性,降低癌细胞表面活性等。甘草用于调和诸药,补气固表,温中,调和药物偏性,不伤正气;且现代医学研究证实,甘草有较强的解毒作用,还有抗溃疡、抗炎症、镇痉镇咳、降血压、降血脂、抗癌作用。
癌症多以热毒壅盛,气滞血瘀,气血两亏为主要证候,故本申请的中药组合物以解毒,健脾,清热为主加之茯苓、苍术、川芎、黄芪,苦参等的抗肿瘤作用,辅以理气化瘀,补益气血为组方大法而组方;本申请中以苦参大苦大寒,清热燥湿重用为君。苦参大苦大寒,其退热泄降,荡涤湿火之效,能杀湿热所生之毒,较之芩、连力量益烈。臣以野菊花、金银花、薄荷疏风清热,以清肺卫之热毒;茯苓、苍术健脾祛湿,以祛脾胃之湿滞。共奏清热燥湿解毒之效以为臣。湿热一去,则阳亦衰微矣。故大队苦寒之中,少佐丁香、肉桂补火助阳以为反佐,防湿去阳微而功亏一篑,且少火亦可生气,可保人之元阳不熄。黄芪、灵芝益气扶正,固本培元。温阳与益气共用,可防止诸药苦寒太过,伤人脾胃。川芎、木香活血行气,通达气血,使气行血畅,壅滞之湿热毒邪自可随气血而去。故共用为佐。甘草甘平缓急,调和诸药以为使。
在药物的选用方面,不用峻厉之品,而以药性平和的药物,且组方构成简单,安全,易用。本中药组合物有扶正固本、活血化瘀、清热解毒、软坚散结之功效,吸收效果好,无临床不良反应,能够提高人体自身免疫力,活血化淤散结,能有效抑制肿瘤生长,避免西药的耐药,防止肿瘤的复发与转移,且成本低廉、制取工艺简便易行。本发明采用不同药性的中药材,进行了科学配伍,药性相适相辅,能达到理想的治疗效果,且安全,能减轻病患痛苦。
本发明所述中药组合物的组方经大小白鼠药效试验证明抗肿瘤效果显著;且药材获取简单,成本相对低廉,具有增强机体免疫功能,抗肿瘤的作用。
本发明采用的制备方法简单,药物提取效果好,利用提取物制成中药组合物的方法简单,方便。
具体实施方式
实施例1
一种用于肿瘤治疗的中药组合物包括以下重量配比的原料制成:苦参8%,野菊花9%,金银花4%,薄荷6%,茯苓6%,苍术17%,肉桂2%,丁香1%,黄芪8%,灵芝10%,川芎13%,木香9%,甘草7%。
该用于肿瘤治疗的中药组合物的制备方法包括:按照上述重量配比称取各中药成分,分别粉碎至粒度至20目过筛后混合均匀;配制浓度为70%的乙醇溶液备用;采用制备的所述浓度为70%的乙醇溶液将混合均匀后的中药浸润至少24h,将浸润后的中药混合物分次加入渗漉桶,轻压铺平;将所述配制的浓度为70%的乙醇溶液加入到渗漉桶中,加至超过药材表面1-2cm,浸泡18-30小时后,将剩余乙醇进行渗漉,保留药渣备用;所得醇液减压浓缩,干燥得浸泡到中药复合粉末A;将所述药渣加2-10倍药渣量的水,水煎提取0.5-2h,离心过滤,药液减压浓缩干燥得到中药复合粉末B,将所述中药复合粉末A和中药复合粉末B混合均匀得到中药组合物。
实施例2
一种用于肿瘤治疗的中药组合物包括以下重量配比的原料制成:苦参7%,野菊花7%,金银花6%,薄荷8%,茯苓8%,苍术15%,肉桂2%,丁香1.5%,黄芪7%,灵芝8%,川芎15%,木香10%,甘草5.5%。
该用于肿瘤治疗的中药组合物的制备方法包括:按照所述重量配比称取川芎、苍术、木香、丁香、肉桂、薄荷加适量挥发油提取溶剂提取挥发油,挥发油提取溶剂用量为6倍所述药材量的水,提取时间2-12小时;提取挥发油后,在40摄氏度以下进行环糊精包合,包合时间6小时;水煎液过滤另器收集作为剩余药液备用;将挥发油提取后得到的药渣与按所述重量配比称取的茯苓,黄芪,野菊花,灵芝,金银花,苦参,甘草加10~15倍药材量的水煎煮2~5次,每次1-2小时;将煎煮得到的药液进行过滤,将过滤后的药液与提取挥发油后得到的剩余药液合并得到中药混合药液;将得到的中药混合药液通过水浴进行浓缩,浓缩至相对密度为1.06-1.08的清膏,加入乙醇使含醇量达60%,静置12小时以上得到中药混合醇液;将所述中药混合醇液进行减压浓缩,干燥后,加入挥发油环糊精包合物制得中药组合物。
实施例3
一种用于肿瘤治疗的中药组合物包括以下重量配比的原料制成:苦参8%,野菊花7%,金银花5%,薄荷6%,茯苓9%,苍术18%,肉桂1.5%,丁香0.5%,黄芪6%,灵芝9%,川芎16%,木香9%,甘草5%。
该用于肿瘤治疗的中药组合物的制备方法包括:按照所述重量配比称取各中药成分。
配制浓度为60%的乙醇溶液备用;将混合均匀的中药中加入6倍量所述配制的乙醇溶液,加热回流提取2次(加热至微沸腾进行回流提取),每次1-2小时,将2次提取液合并,减压回收乙醇后进行浓缩干燥,得到中药组合物。
实施例4
一种用于肿瘤治疗的中药组合物包括以下重量配比的原料制成:苦参6%,野菊花9%,金银花8%,薄荷5%,茯苓9%,苍术19%,肉桂1%,丁香1%,黄芪6%,灵芝15%,川芎11%,木香9%,甘草10%。
该用于肿瘤治疗的中药组合物的制备方法包括:按照上述重量配比称取各中药成分,分别粉碎至粒度至30目过筛后混合均匀;配制浓度为650%的乙醇溶液备用;采用制备的所述浓度为65%的乙醇溶液将混合均匀后的中药浸润36h,将浸润后的中药混合物分次加入渗漉桶,轻压铺平;将所述配制的浓度为65%的乙醇溶液加入到渗漉桶中,加至超过药材表面1-2cm,浸泡18小时后,将剩余乙醇进行渗漉,保留药渣备用;所得醇液减压浓缩,干燥得浸泡到中药复合粉末A;将所述药渣加5倍药渣量的水,水煎提取1-2h,离心过滤,药液减压浓缩干燥得到中药复合粉末B,将所述中药复合粉末A和中药复合粉末B混合均匀得到中药组合物。
实施例5
一种用于肿瘤治疗的中药组合物包括以下重量配比的原料制成:苦参9%,野菊花8%,金银花3%,薄荷9%,茯苓8%,苍术16.5%,肉桂1%,丁香1%,黄芪9%,灵芝9%,川芎13.5%,木香10%,甘草3%。
该用于肿瘤治疗的中药组合物的制备方法包括:按照所述重量配比称取川芎、苍术、木香、丁香、肉桂、薄荷加适量挥发油提取溶剂提取挥发油,挥发油提取溶剂用量为4倍所述药材量的水,提取时间2-12小时;提取挥发油后,在40摄氏度以下进行环糊精包合,包合时间5小时;水煎液过滤另器收集作为剩余药液备用;将挥发油提取后得到的药渣与按所述重量配比称取的茯苓,黄芪,野菊花,灵芝,金银花,苦参,甘草加10~15倍药材量的水煎煮2~5次,每次1-2小时;将煎煮得到的药液进行过滤,将过滤后的药液与提取挥发油后得到的剩余药液合并得到中药混合药液;将得到的中药混合药液通过水浴进行浓缩,浓缩至相对密度为1.06-1.08的清膏,加入乙醇使含醇量达60%,静置12小时以上得到中药混合醇液;将所述中药混合醇液进行减压浓缩,干燥后,加入挥发油环糊精包合物制得中药组合物。
药效试验:
为了验证本发明在肿瘤治疗中的效果,采用实施例1和实施例2方法制得的中药组合物用于以下药效试验。
本发明的用于肿瘤治疗的中药组合物成人临床推荐剂量为生药量7.6g生药/60kg/d,换算成裸小鼠等效用量为1.4g/kg/d。试验中采用2.8、1.4、0.7g/kg/d三个剂量组(分别相当于人临床用量的2倍、等倍、1/2倍)。
本发明的用于肿瘤治疗的中药组合物对人肺腺癌细胞株(A549)裸小鼠模型的抑制作用。
本发明的用于肿瘤治疗的中药组合物2个实施例(简称中药组合物1号,中药组合物2号)所得样品各剂量组肿瘤体积在给药后与模型对照组比较均有所下降,在给药8天后肿瘤体积与模型对照组比较下降明显(P<0.01,P<0.05)。与模型对照组比较,中药组合物1号的高剂量组和中药组合物2号的中剂量组的相对肿瘤增值率在28-70之间。2个样品各剂量组瘤块重量与模型对照组比较下降明显(P<0.01)。综合本次试验数据后发现:2号样品中剂量组肿瘤体积在给药4-20天5个检测时间点与模型对照组比较均有差异,其相对肿瘤增值率在给药8天后在40以下,该给药组瘤块重量最小。
1试验材料
1.1受试药物中药组合物1号,中药组合物2号;用法用量:口服,原临床推荐剂量为每日生药量7.6g。
1.2阳性对照药复方环磷酰胺片,生产单位:通化茂祥制药有限公司。适应症:恶性淋巴瘤、多发性骨髓瘤、淋巴细胞白血病、神母细胞瘤、卵巢癌、乳癌以及各种肉瘤及肺癌等。批号:160702,生产日期:2016.07.25,有效期至:2018.06。成分:复方制剂,组份为环磷酰胺(50mg)和人参茎叶总皂苷(50mg)。性状:肠溶衣片,除去包衣后显黄褐色或灰褐色。规格:每片含环磷酰胺50mg,人参茎叶总皂苷50mg,12片/板,2板/盒。用法用量:口服,成人一次1片,一日3~4次。储存条件:遮光,密封,30℃以下保存。
1.3试验动物
1.4肿瘤细胞株
1.5试验试剂
试剂名称 | 批号 | 生产厂家 | 用途 |
PBS磷酸缓冲液 | 1789842 | 美国Gibco | 冲洗细胞 |
DMEM高糖培养基 | 8116489 | 美国Gibco | 培养细胞 |
胎牛血清 | 1390781 | 美国Gibco | 培养细胞 |
双抗 | J130061 | Hyclore | 培养细胞 |
0.25%胰酶 | 1616025 | 美国Gibco | 细胞消化、传代 |
1.6试验仪器
1.7试验主要耗材
名称 | 规格 |
塑料培养瓶 | 225cm<sup>2</sup> |
移液枪枪头 | 黄色(200ul)、蓝色(1000ul) |
离心管 | 1ml、5ml |
2试验方法
2.1剂量设计
2.1.1用于肿瘤治疗的中药组合物:成人临床推荐剂量为7.6g生药/60kg/d,试验中按人与动物体表面积换算,小鼠用量为人用量的11倍,小鼠的给药剂量为(7.6/60)×11=1.4g生药/kg/d,送检药液浓度配成2g生药/ml,小鼠的给药剂量换为体积为(1.4/2)*1=0.7ml/kg/d,故三种提取物大、中、小剂量为1.4ml/kg/d、0.7ml/kg/d、0.35ml/kg/d(分别相当于人临床用量的2倍、等倍及1/2倍)。
2.1.2复方环磷酰胺片:成人临床推荐剂量175mg/60kg/d,试验中按人与动物体表面积换算,小鼠用量按人用量的11倍计算,小鼠的给药剂量为(175/60)×11=32mg/kg/d。
2.2人肺腺癌细胞株(A549)的培养细胞株培养在完全培养基中(DMEM培养液+10%胎牛血清,pH7.2),置于37℃5%CO2恒温培养箱内,每天更换培养液,细胞培养至80%-90%融合率,0.25%胰蛋白酶消化,离心后传代,待细胞培养至一定数量,用PBS稀释成肿瘤细胞悬液接种于试验动物体内。
2.3细胞体外活性检测及肿瘤细胞悬浮液的制备在无菌条件下取生长良好的A549肿瘤细胞,用0.25%胰蛋白酶消化,离心后,混悬细胞,采用台盼蓝染色法,使用全自动细胞计数仪检测细胞活性并计数。用PBS稀释成2×107个细胞/ml浓度的肿瘤细胞悬浮液。
2.4接种A549肿瘤细胞制备人肺癌移植瘤模型取体重为18±2g的裸小鼠,雌雄各半,在实验动物中心适应性饲养7日。在无菌条件下,将裸鼠用75%乙醇皮肤消毒后,在裸鼠右腋皮下接种人肺腺癌A549细胞悬液0.2ml,接种后将裸鼠送回笼具,定期观察小鼠的精神、饮食及排便等情况。接种1周左右,可见接种部位皮下长出米粒大小的硬结,为移植瘤模型建成。
2.5分组及给药接种肿瘤细胞2周后,挑选瘤块、体重均匀的裸小鼠,随机分为8组,分别为模型对照组、环磷酰胺阳性对照组、中药组合物1号高、中、低三个剂量组、中药组合物2号高、中、低三个剂量组,每组7只,分组当天开始给药,每日一次,给药量为0.2ml/10g,口服给药,连续给药3周。
2.6观察指标给药当天测定裸鼠的体重、肿瘤体积,隔3日测定一次,三周后称重处死裸小鼠,取出肿瘤组织称重,计算每组平均瘤重、肿瘤生长抑制率、肿瘤体积、相对肿瘤体积、相对肿瘤增殖率。
计算方法:
肿瘤体积(tumor volume,TV)的计算公式为:V=1/2×a×b2。其中a、b分别表示长宽高。
相对肿瘤体积(relative tumor volume,RTV)的计算公式为:RTV=Vt/V0。其中V0为分笼给药时(即d0)测量所得肿瘤体积,Vt为每一次测量时的肿瘤体积。
相对肿瘤增殖率T/C(%)(抗肿瘤活性的评价指标)的计算公式为:T/C%=TRTV/CRTV×100%。(TRTV:治疗组RTV;CRTV:阴性对照组RTV)。
2.7统计学处理实验数据经Excel表建库整理后,用SPSS13.0统计软件包进行分析,计量资料以X±s表示,两组间比较用t检验,多组间比较用单因素方差分析,P<0.05为差异有统计学意义。
3试验结果
3.1 A549肿瘤细胞计数(接种时细胞浓度)将细胞离心后,用PBS混悬,取10ul细胞悬液稀释一倍后加20ul台盼蓝染色剂,吹打均匀后加入细胞计数板内,插入全自动细胞计数仪内进行检测。总细胞数:2.14×107/ml;活细胞数:1.5×107/ml;死细胞数:6.42×106/ml;细胞存活率:95.04%。
3.2对人肺腺癌细胞株(A549)裸小鼠模型肿瘤体积生长情况的影响
Table 1 Effect of Ai Kang tablets on tumor volume in BALB/c nude miceinfected with human lung adenocarcinoma cancer cell(A549)(n=7)mm3
注:与模型对照组比较,*P<0.05,**P<0.01;
从结果可以看出中药组合物2种工艺样品在给药2天后起肿瘤体积与模型对照组比较均有所下降。2个样品在给药8-20天后肿瘤体积与模型对照组比较明显下降(P<0.01,P<0.05),其中2号药品中剂量组肿瘤体积在给药4-20天5个检测时间点与模型对照组比较均有差异(P<0.01),从数值上看差异也最为显著。
3.3对人肺腺癌细胞株(A549)裸小鼠相对肿瘤增值体积(RTV)及相对肿瘤增值率的影响
Table 2 Effect of Ai Kang tablets on the relative tumor volume andthe relative proliferationrate in BALB/c nude mice infected with human lungadenocarcinoma cancer cell(A549)(n=7)
注:与模型对照组比较,*P<0.05,**P<0.01;
结果显示:艾康2号中剂量组的相对肿瘤增值体积在给药期间与模型对照组比较有差异(P<0.05),其余各用药组与模型组无差异。与模型对照组比较,艾康1号高剂量组、艾康2号中剂量组的相对肿瘤增值率在28-70之间,其余用药组的相对肿瘤增值率在50-90之间。
3.4对人肺腺癌细胞株(A549)裸小鼠相对肿瘤重量的影响
Table 3 Effect of Ai Kang tablets on tumor weight in BALB/c nude miceinfected with human lung adenocarcinoma cancer cell(A549)(n=7)(g)
注:与模型对照组比较,*P<0.05,**P<0.01;
中药组合物各剂量组瘤块重量与模型对照组比较均有差异(P<0.01),艾康2号中剂量组肿瘤块重量最小。
4结论
中药组合物对人肺腺癌细胞株(A549)裸鼠的肿瘤增长有一定的抑制作用。2种提取工艺制得的样品均可明显降低裸鼠肿瘤体积、相对肿瘤增值体积、肿瘤增值率、肿瘤重量。整体药效从高到低排序为:2号样品〉1号样品〉复方环磷酰胺片。
以上所述仅为本发明的优选实施例,对本发明具有说明性,而非限制性,本领域技术人员应理解,在本发明权利要求所限定的范围内可对其进行适应性的改变,但均应落入本发明的保护范围之内。
Claims (12)
1.一种用于肺部肿瘤治疗的中药组合物,其特征在于:所述用于肺部肿瘤治疗的中药组合物由以下重量配比的原料制成:
苦参3%-12%,野菊花5%-15%,金银花2%-12%,薄荷5%-15%,茯苓5%-15%,苍术10%-20%,肉桂0.5%-3%,丁香0.5%-3%,黄芪3%-12%,灵芝5%-15%,川芎10%-20%,木香5%-12%,甘草2%-10%。
2.根据权利要求1所述的用于肺部肿瘤治疗的中药组合物,其特征在于:所述用于肺部肿瘤治疗的中药组合物由以下重量配比的原料制成:
苦参5%-10%,野菊花5%-10%,金银花3%-8%,薄荷5%-10%,茯苓5%-10%,苍术12%-20%,肉桂0.5%-3%,丁香0.5%-3%,黄芪5%-10%,灵芝5%-10%,川芎11%-15%,木香8%-12%,甘草3%-8%。
3.根据权利要求1所述的用于肺部肿瘤治疗的中药组合物,其特征在于,所述用于肺部肿瘤治疗的中药组合物由以下重量配比的原料制成:
苦参6%-10%,野菊花6%-9%,金银花3%-6%,薄荷6%-9%,茯苓6%-9%,苍术15%-18%,肉桂1%-3%,丁香0.5%-1.5%,黄芪6%-10%,灵芝6%-10%,川芎12%-15%,木香8%-11%,甘草3%-6%。
4.根据权利要求1-3任一项所述的用于肺部肿瘤治疗的中药组合物,其特征在于,所述用于肺部肿瘤治疗的中药组合物的剂型为:注射剂、蜜炼丸剂、水合丸剂、胶囊、片剂、滴丸剂、散剂、口服液体药物、凝胶剂、浸膏剂或膜剂。
5.根据权利要求1-3中任一项所述的用于肺部肿瘤治疗的中药组合物的制备方法,其特征在于,所述制备方法包括以下步骤:
步骤(1) 按照所述重量配比称取各中药成分,分别粉碎至粒度至10目-100目过筛后混合均匀;
步骤(2)配制浓度为40%-95%的乙醇溶液备用;采用制备的所述浓度为40%-95%的乙醇溶液将混合均匀后的中药浸润10-48小时,将浸润后的中药混合物分次加入渗漉桶,轻压铺平;
步骤(3)将所述配制的浓度为40%-95%的乙醇溶液加入到步骤(2)中的渗漉桶中,加至超过药材表面1-2cm,浸泡预设时间后,将剩余乙醇进行渗漉,保留药渣备用;所得醇液减压浓缩,干燥得到中药复合粉末A;
步骤(4)将所述药渣加2-10倍药渣量的水,水煎提取0.5-2h,离心过滤,药液减压浓缩干燥得到中药复合粉末B,将所述中药复合粉末A和中药复合粉末B混合均匀得到中药组合物。
6.根据权利要求5所述的用于肺部肿瘤治疗的中药组合物的制备方法,其特征在于,所述步骤(1)中各种药材粉碎粒度至20-40目;所述步骤(2)和(3)中所配制的乙醇浓度为60%-80%。
7.根据权利要求6所述的用于肺部肿瘤治疗的中药组合物的制备方法,其特征在于,所述步骤(2)中将混合均匀后的中药浸润18-30小时;所述步骤(3)中浸泡时间为2-48小时。
8.根据权利要求1-3中任一项所述的一种用于肺部肿瘤治疗的中药组合物的制备方法,其特征在于,所述制备方法包括以下步骤:
步骤(1)按照所述重量配比称取川芎、苍术、木香、丁香、肉桂、薄荷加适量水提取挥发油后,加环糊精包合,水煎液过滤另器收集作为剩余药液备用;
步骤(2)将挥发油提取后得到的药渣与按所述重量配比称取的茯苓,黄芪,野菊花,灵芝,金银花,苦参,甘草加水煎煮,过滤药液,将过滤后的药液与提取挥发油后得到的剩余药液合并得到中药混合药液;
步骤(3)将得到的中药混合药液通过水浴浓缩至清膏,醇沉,加乙醇使含醇量达到50%-80%得到中药混合醇液;
步骤(4)将所述中药混合醇液进行减压浓缩,干燥后,加入挥发油环糊精包合物制得中药组合物。
9.根据权利要求8所述的用于肺部肿瘤治疗的中药组合物的制备方法,其特征在于,所述步骤(1)中挥发油提取溶剂用量为4-15倍所述药材量的水,提取时间2-12小时;得到的挥发油在40摄氏度以下进行环糊精包合,包合时间1~10小时。
10.根据权利要求8所述的用于肺部肿瘤治疗的中药组合物的制备方法,其特征在于,所述步骤(2)包括:将挥发油提取后得到的药渣与按所述重量配比称取的茯苓,黄芪,野菊花,灵芝,金银花,苦参,甘草加10~15倍药材量的水煎煮2~5次,每次1-2小时;将煎煮得到的药液进行过滤,将过滤后的药液与提取挥发油后得到的剩余药液合并得到中药混合药液。
11.根据权利要求8所述的用于肺部肿瘤治疗的中药组合物的制备方法,其特征在于,所述步骤(3)包括:将得到的中药混合药液通过水浴进行浓缩,浓缩至相对密度为1.06-1.08的清膏,加入乙醇使含醇量达60%,静置12小时以上得到中药混合醇液。
12.根据权利要求1-3中任一项所述的用于肺部肿瘤治疗的中药组合物的制备方法,其特征在于,所述制备方法包括以下步骤:
步骤(1)按照所述重量配比称取各中药成分;
步骤(2)配制浓度为40%-80%的乙醇溶液备用;将混合均匀的中药中加入所述配制的乙醇溶液,加热回流提取1-4次,每次1-2小时,将提取液合并,减压回收乙醇后进行浓缩干燥,得到中药组合物。
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710147162.1A CN108567820B (zh) | 2017-03-13 | 2017-03-13 | 一种用于肿瘤治疗的中药组合物及其制备方法 |
PCT/CN2017/101223 WO2018166151A1 (zh) | 2017-03-13 | 2017-09-11 | 一种用于治疗肿瘤的中药组合物及其制备方法和用途 |
KR1020197015690A KR20190124197A (ko) | 2017-03-13 | 2017-09-11 | 종양 치료용 한약 조성물 및 그 제조방법 및 응용 |
US16/462,073 US11065291B2 (en) | 2017-03-13 | 2017-09-11 | Traditional Chinese medicine composition for treating tumours, preparation method therefor and use thereof |
EP17900742.2A EP3597207B1 (en) | 2017-03-13 | 2017-09-11 | Traditional chinese medicine composition for treating tumours, preparation method therefor and use thereof |
JP2019547748A JP2019535833A (ja) | 2017-03-13 | 2017-09-11 | 腫瘍治療用の漢方薬組成物及びその製造方法と用途 |
AU2017403418A AU2017403418A1 (en) | 2017-03-13 | 2017-09-11 | Traditional Chinese medicine composition for treating tumours, preparation method therefor and use thereof |
CA3046136A CA3046136A1 (en) | 2017-03-13 | 2017-09-11 | Traditional chinese medicine composition for treating tumors, preparation method thereof and use thereof |
US17/379,980 US20210346452A1 (en) | 2017-03-13 | 2021-07-19 | Traditional chinese medicine composition for treating tumours, preparation method therefor and use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710147162.1A CN108567820B (zh) | 2017-03-13 | 2017-03-13 | 一种用于肿瘤治疗的中药组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108567820A CN108567820A (zh) | 2018-09-25 |
CN108567820B true CN108567820B (zh) | 2021-07-09 |
Family
ID=63522749
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710147162.1A Active CN108567820B (zh) | 2017-03-13 | 2017-03-13 | 一种用于肿瘤治疗的中药组合物及其制备方法 |
Country Status (8)
Country | Link |
---|---|
US (2) | US11065291B2 (zh) |
EP (1) | EP3597207B1 (zh) |
JP (1) | JP2019535833A (zh) |
KR (1) | KR20190124197A (zh) |
CN (1) | CN108567820B (zh) |
AU (1) | AU2017403418A1 (zh) |
CA (1) | CA3046136A1 (zh) |
WO (1) | WO2018166151A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108567820B (zh) | 2017-03-13 | 2021-07-09 | 左安刚 | 一种用于肿瘤治疗的中药组合物及其制备方法 |
TWI732309B (zh) * | 2018-10-10 | 2021-07-01 | 蘇娥 梁 | 補虛損保健品組合物及其製備方法和其應用 |
CN111743994A (zh) * | 2020-07-31 | 2020-10-09 | 南京同仁堂药业有限责任公司 | 一种温中健脾的中药制剂及其制备方法 |
CN113855778B (zh) * | 2021-09-18 | 2022-05-13 | 河南中医药大学 | 一种治疗脾肾阳衰顽痰痼血型食管癌的中药 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105265665A (zh) * | 2014-06-10 | 2016-01-27 | 孙继芝 | 一种防治贫血和各种肿瘤的内服养生茶 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101483440B1 (ko) * | 2008-05-02 | 2015-01-19 | (주)아모레퍼시픽 | 포제를 활용한 약용식물 추출물 및 이를 함유하는 피부외용제 조성물 |
CN101612383B (zh) | 2009-07-21 | 2011-03-30 | 吕启贵 | 一种治疗胃癌、食道癌的药物及其制备方法 |
CN101721619A (zh) | 2010-01-19 | 2010-06-09 | 泰一和浦(北京)中医药研究院有限公司 | 一种治疗脑干肿瘤的外用中药组合物及其制备方法 |
CN109432344A (zh) | 2013-03-11 | 2019-03-08 | 肖鸣春 | “化湿药”在制备抗霉菌的药物或保健品中的应用 |
CN104013920A (zh) | 2014-06-26 | 2014-09-03 | 王芬 | 一种治疗胃癌的中药组合物 |
CN104800459A (zh) | 2015-05-14 | 2015-07-29 | 奉化科创科技服务有限公司 | 治疗胃癌的中药 |
CN106310120A (zh) * | 2016-08-31 | 2017-01-11 | 陈爱红 | 一种广普型中药组合物水剂及其制备方法 |
CN108567820B (zh) | 2017-03-13 | 2021-07-09 | 左安刚 | 一种用于肿瘤治疗的中药组合物及其制备方法 |
-
2017
- 2017-03-13 CN CN201710147162.1A patent/CN108567820B/zh active Active
- 2017-09-11 CA CA3046136A patent/CA3046136A1/en not_active Abandoned
- 2017-09-11 US US16/462,073 patent/US11065291B2/en active Active
- 2017-09-11 AU AU2017403418A patent/AU2017403418A1/en not_active Abandoned
- 2017-09-11 KR KR1020197015690A patent/KR20190124197A/ko not_active Application Discontinuation
- 2017-09-11 EP EP17900742.2A patent/EP3597207B1/en active Active
- 2017-09-11 WO PCT/CN2017/101223 patent/WO2018166151A1/zh unknown
- 2017-09-11 JP JP2019547748A patent/JP2019535833A/ja active Pending
-
2021
- 2021-07-19 US US17/379,980 patent/US20210346452A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105265665A (zh) * | 2014-06-10 | 2016-01-27 | 孙继芝 | 一种防治贫血和各种肿瘤的内服养生茶 |
Non-Patent Citations (2)
Title |
---|
中药金安与顺铂诱导小鼠Lewis肺癌凋亡的研究;周彩虹等;《中国肿瘤》;20031231;第12卷(第3期);第169-171页 * |
常用抗肿瘤中药的临床应用与规律探讨;凌汶静;《中国优秀硕士学位论文全文数据库 医药卫生科技辑》;20151215(第12期);第22-54页表格 * |
Also Published As
Publication number | Publication date |
---|---|
CN108567820A (zh) | 2018-09-25 |
JP2019535833A (ja) | 2019-12-12 |
EP3597207B1 (en) | 2022-04-20 |
US20190328813A1 (en) | 2019-10-31 |
US20210346452A1 (en) | 2021-11-11 |
AU2017403418A1 (en) | 2019-06-06 |
WO2018166151A1 (zh) | 2018-09-20 |
KR20190124197A (ko) | 2019-11-04 |
CA3046136A1 (en) | 2018-09-20 |
US11065291B2 (en) | 2021-07-20 |
EP3597207A1 (en) | 2020-01-22 |
EP3597207A4 (en) | 2020-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108567820B (zh) | 一种用于肿瘤治疗的中药组合物及其制备方法 | |
CN103768398B (zh) | 一种治疗晚期肺肿瘤的中药组合物 | |
WO2013071727A1 (zh) | 抗肿瘤的中药组合物 | |
CN105560372A (zh) | 一种治疗鼻炎的中药喷雾剂及其制备方法 | |
Li | Chinese herbal medicine | |
CN106310023A (zh) | 治疗小细胞肺癌的药物、制备方法及其用途 | |
CN108452240B (zh) | 一种抗肿瘤的中药组合物及其应用 | |
CN104056242A (zh) | 一种治疗急性胆囊炎的中药组合物及其制备方法 | |
CN104095912B (zh) | 治疗风湿骨病的中成药的制备方法 | |
CN105902897A (zh) | 一种治疗胰腺癌的药物制剂及其用途 | |
CN105327267A (zh) | 一种治疗肿瘤的中药酒剂及其制备方法 | |
CN111588749A (zh) | 中药组合物的新用途 | |
CN105617319A (zh) | 一种制备治疗急性胆囊炎的中药组合物的方法 | |
CN103191268B (zh) | 一种治疗肺癌的中药组合物 | |
CN113101331B (zh) | 一种百里香药茶及其制备方法和应用 | |
CN113952435B (zh) | 一种辅助治疗肝癌的中药组合物及其制备方法 | |
CN117379497B (zh) | 中药组合物在制备抑制幽门螺杆菌的药物中的用途 | |
JP6708916B1 (ja) | 補気調節用チワン族医薬品組成物及びその調製方法 | |
CN100473403C (zh) | 一种治疗癌症的胶囊 | |
CN105663551A (zh) | 胰腺癌患者术后服用的中药制剂及制法 | |
CN105998979A (zh) | 一种治疗肺肾阴虚型慢性咽炎的中药组合物及方法 | |
CN105770515A (zh) | 一种治疗前列腺炎的中药组合物及其制备方法 | |
WO2023103126A1 (zh) | 一种具有抗癌作用的中药组合物及其制备方法 | |
KR20230159726A (ko) | 환 형태의 비염 및 기관지염 치료제 제조방법 | |
CN118806832A (zh) | 一种用于晚期原发性肝癌的中药组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220228 Address after: 100089 3299, floor 3, building 1, building 7, Changyun palace, Haidian District, Beijing Patentee after: Anhua Hengtai (Beijing) Pharmaceutical Technology Co.,Ltd. Address before: 100029 room 1216, building 1, yard 5, Anding Road, Chaoyang District, Beijing Patentee before: Zuo Angang Patentee before: Zuo Shixu Patentee before: Zhao Na |
|
TR01 | Transfer of patent right |